Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Trial Information

Pharmacokinetics and Metabolism of [14C] BMS-690514 in Healthy Male Subjects

Inclusion Criteria:

- Healthy male subjects

- Body mass index (BMS) of 18 - 30 kg/m², inclusive

Exclusion Criteria:

- Radiation exposure from diagnostic X-rays (except dental X-rays) in the last year or
from clinical trials in the last 5 years

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Single dose pharmacokinetics of BMS-690514 and radioactivity in plasma and urine

Outcome Time Frame:

measured for 10 days post-dose

Safety Issue:

Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb

Authority:

Switzerland: Swissmedic

Study ID:

CA187-003

NCT ID:

NCT00578916

Start Date:

January 2008

Completion Date: